NOTTINGHAM, England--(BUSINESS WIRE)--Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards ...
Bristol, UK, 10th December, 2025 - Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people living with ...
Funding led by Eos Advisory and Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, signals strong investor confidence despite challenging market conditions. The round ...
Insider has profiled some of the most promising spin-outs from Midlands universities, with businesses developing innovative technology that accelerates recovery from surgery, alleviates the symptoms ...
A wrist device tested by Scottish singer Lewis Capaldi has been shown to reduce tics in those with Tourette's syndrome. The Neupulse device, developed by the University of Nottingham, delivers ...
Neupulse, a neurotherapeutics company developing solutions for brain health conditions such as Tourette's syndrome, has raised £3m to accelerate its path to market. The funding round was led by Eos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results